Evosep acquired by Nordic Capital
Evosep, headquarted in Odense, is a leading innovator in sample preparation and separation solutions for LCMS-based proteomics.
Evosep's technology enables high-throughput, robust, and reproducible LC-MS–based proteomics workflows, driving efficiency and scalability for translational research and biopharma applications. By simplifying complex proteomics processes, Evosep empowers laboratories to deliver deeper biological insights and accelerate discoveries that benefit modern healthcare and life sciences.
Nordic Capital is a leading international private equity investor with a strong track record of investing in healthcare and technology companies.
The transaction represents a successful exit for Novo Holdings and EIFO who have both been long-standing investors in Evosep.
The transaction is expected to close in Q4 2025.
Plesner's core M&A team consisted of Thomas Holst Laursen, Mikkel Rostock-Jensen, Morten Stig Ottesen, Louise Lund Amris and Marcus Nimmo Allerup Bogh.